Coherus director granted RSUs and stock options

Coherus Oncology, Inc. director Ryan Michael Lee reported receiving new equity-based compensation.

Rhea-AI Filing Summary

Coherus Oncology, Inc. director Ryan Michael Lee reported receiving new equity-based compensation. He was granted 30,000 restricted stock units (RSUs), each representing one share of common stock upon vesting, and now holds 30,000 common shares directly after this award.

According to the filing, 100% of these RSUs will vest on the one-year anniversary of June 3, 2026, assuming he continues his service with the company. Lee also received stock options for 60,000 shares of common stock at an exercise price of $1.45 per share, which vest and become exercisable in full on June 3, 2027, subject to continued service.

Insights

Equity compensation analyst

Director received time-based RSUs and options as routine equity compensation.

The filing shows Ryan Michael Lee, a director of Coherus Oncology, Inc., receiving 30,000 RSUs and options for 60,000 shares at an exercise price of $1.45. Both awards are time-based and tied to continued board service.

The RSUs cliff-vest 100% on the one-year anniversary of June 3, 2026, while the options cliff-vest 100% on June 3, 2027. Because these are grants with zero purchase price at grant and no same-day sales, they are standard compensation rather than active market trades.

This type of equity package aligns the director’s incentives with shareholders over the next one to two years. Any financial impact for existing investors depends on overall share count and future company performance, which are not detailed in this filing excerpt.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 2 txns

Insider Ryan Michael Lee

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	60,000	$0.00	$0.00
Grant/Award	Common Stock	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 60,000 contracts (Direct); Common Stock — 30,000 shares (Direct)

Footnotes (2)

1. F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
2. F2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.

Key Figures

RSUs granted: 30,000 units Common shares after RSU grant: 30,000 shares Options granted: 60,000 options +3 more

6 metrics

RSUs granted 30,000 units Restricted stock units awarded to director

Common shares after RSU grant 30,000 shares Total common stock holdings following RSU award

Options granted 60,000 options Stock options awarded to buy common stock

Option exercise price $1.45 per share Exercise price for 60,000 stock options

RSU vesting date One-year anniversary of June 3, 2026 Cliff vesting of 30,000 RSUs

Option vesting date June 3, 2027 Cliff vesting and exercisability of 60,000 options

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), vest, exercisable, +1 more

5 terms

restricted stock units ("RSUs") financial

"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of 1.4500"

vest financial

"100% of the RSUs shall vest on the one year anniversary of June 3, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercisable financial

"The underlying shares vest and become exercisable as to 100% of the total number"

exercise price financial

"conversion_or_exercise_price of 1.4500 per share for the stock option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Coherus Oncology (CHRS) director Ryan Michael Lee receive in this Form 4?

Ryan Michael Lee received equity-based compensation consisting of 30,000 restricted stock units and stock options for 60,000 shares. These awards increase his potential ownership in Coherus Oncology, Inc., subject to future vesting conditions tied to his continued service with the company.

How many Coherus Oncology (CHRS) RSUs were granted to Ryan Michael Lee and how do they work?

He was granted 30,000 restricted stock units, each convertible into one share of common stock upon vesting. The RSUs carry no purchase price at grant and are designed as compensation, giving him future shares if he remains in service through the vesting date.

When do Ryan Michael Lee’s Coherus Oncology (CHRS) RSUs vest?

All 30,000 RSUs are scheduled to vest 100% on the one-year anniversary of June 3, 2026. Vesting is conditioned on his continued service relationship with Coherus Oncology, Inc. through that date, meaning he must remain in his role to receive the shares.

What stock options did Ryan Michael Lee receive from Coherus Oncology (CHRS)?

He received stock options covering 60,000 shares of Coherus Oncology common stock with an exercise price of $1.45 per share. These options give him the right, but not the obligation, to buy shares at that price once they vest and become exercisable.

When do Ryan Michael Lee’s Coherus Oncology (CHRS) stock options vest and become exercisable?

The stock options for 60,000 shares vest and become exercisable as to 100% of the underlying shares on June 3, 2027. This vesting is contingent on his continued service relationship with Coherus Oncology, Inc. through that vesting date as described in the filing.

Does this Coherus Oncology (CHRS) Form 4 show any stock being bought or sold on the market?

The Form 4 reflects grant or award acquisitions of RSUs and stock options, not open-market buying or selling. The transaction code is “A,” indicating compensation awards with a zero purchase price at grant, rather than discretionary market purchases or sales by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Michael Lee

(Last) (First) (Middle)

C/O COHERUS ONCOLOGY, INC.

333 TWIN DOLPHIN DRIVE, SUITE 600

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Coherus Oncology, Inc. [ CHRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		30,000(1)	A	$0	30,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.45	06/05/2026		A		60,000		(2)	06/05/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.

2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.

	/s/ Bryan McMichael, as Attorney-in-Fact for Michael Lee Ryan	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)